YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Mar 05, 16:00
4489.40
-84.9 (-1.86%)
VOLUME 29,961
LIVE
NSE
Mar 05, 15:59
4492.50
-82.55 (-1.8%)
VOLUME 826,369
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

1.34 pm | 05 Mar 2021 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated ...

Dr Reddy's launches stomach, esophagus problems treatment drug in the US

12.34 pm | 22 Feb 2021 |  Source: PTI

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and ...

Dr Reddy's begins process to obtain emergency use authorisation for Sputnik V

6.30 pm | 19 Feb 2021 |  Source: PTI

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 voluntee...

Dr Reddy's launches Fluphenazine Hydrochloride tablets in US

12.05 pm | 18 Feb 2021 |  Source: PTI

The product is a therapeutic equivalent generic version of Prolixin tablets approved by the US Food and Drug Administration (USFDA)....

Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

11.48 pm | 09 Feb 2021 |  Source: Moneycontrol.com

Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research ...

Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

10.52 pm | 09 Feb 2021 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated ...

Cadila: COVID vaccine to be the key differentiator in the near term

9.23 am | 09 Feb 2021 |  Source: Moneycontrol.com

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion...

Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

3.44 pm | 08 Feb 2021 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research ...

Will Dr Reddy's be able to reap the benefit of Sputnik V COVID-19 vaccine?

5.06 pm | 05 Feb 2021 |  Source: Moneycontrol.com

The vaccine windfall could be a one-time opportunity, depending on how quickly the company brings it to market, besides resolving cold chain and logis...

Weekly Tactical Pick | Dr Reddy's Laboratories

9.23 am | 05 Feb 2021 |  Source: Moneycontrol.com

Vaccine scope, strong product pipeline to act as tonic for Dr Reddy's Laboratories...

Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

5.22 pm | 04 Feb 2021 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dat...

Neutral Dr Reddy’s Labs; target of Rs 5070: Motilal Oswal

9.09 pm | 02 Feb 2021 |  Source: Moneycontrol.com

Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 5070 in its research report dated January 30, 2021....

Dr Reddys Labs Standalone December 2020 Net Sales at Rs 3,408.20 crore, up 11.96% Y-o-Y

9.22 am | 02 Feb 2021 |  Source: Moneycontrol.com

NULL...

Budget 2021 | Rs 35,000 crore allotment for COVID-19 vaccination brings cheers to vaccine makers

7.43 pm | 01 Feb 2021 |  Source: Moneycontrol.com

Adar Poonawalla, CEO, Serum Institute of India (SII) called the spending on healthcare infrastructure and vaccine by countries as the best bang for th...

Union Budget 2021: Healthcare spending boost led by COVID-19 vaccination, drinking water, sanitation

3.36 pm | 01 Feb 2021 |  Source: Moneycontrol.com

The increase was primarily led by Rs 35,000 crore allotment for COVID-19 vaccines and Rs 21,158 crore allocation to drinking water and sanitation. In ...

Dr Reddy’s: Should we look beyond impairments?

10.16 pm | 31 Jan 2021 |  Source: Moneycontrol.com

Large part of impairment charge taken by Dr Reddy's is explained by the erosion in the value of Nuvaring due to the launch of the additional gener...

Pharma wrap: Three more vaccines to be available in India soon

1.58 pm | 31 Jan 2021 |  Source: Moneycontrol.com

The data from clinical trials of Johnson & Johnson and Novavax which were announced this week were also positive, increasing the chances of the va...

COVID-19: Dr Reddy's expects to launch Sputnik V vaccine in India by March-end

6.45 pm | 29 Jan 2021 |  Source: Moneycontrol.com

The Russian vaccine is priced at $10 (Rs 720) per shot. If the drugs controller grants approval, the vaccine will become the third to be tried in ...

Dr Reddy's Labs Q3 profit at Rs 20 crore, revenue rises 12% YoY

12.08 pm | 29 Jan 2021 |  Source: Moneycontrol.com

The company said the Q3FY21 PAT was impacted primarily due to the non-recognition of deferred tax assets on impairment....

Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

7.28 am | 29 Jan 2021 |  Source: Moneycontrol.com

Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, le...

1 2
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.